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Abstract
Background: Reactivation of silenced tumor suppressor genes by DNMT inhibitors has provided an alternative
approach to cancer therapy. However, DNMT inhibitors have also been shown to induce or enhance tumorigenesis
via DNA hypomethylation-induced oncogene activation and chromosomal instability. To develop more specific
DNMT inhibitors for efficient cancer therapy, we compared the effects of peptides designed to specifically disrupt
the interaction of DNMT1 with different proteins.
Findings: Our data indicated that the use of an unspecific DNMT inhibitor (5aza-2deoxycytidine), a DNMT1 inhibitor
(procainamide) or peptides disrupting the DNMT1/PCNA, DNMT1/EZH2, DNMT1/HDAC1, DNMT1/DNMT3b and
DNMT1/HP1 interactions promoted or enhanced in vivo tumorigenesis in a mouse glioma model. In contrast, a
peptide disrupting the DNMT1/DMAP1 interaction, which per se did not affect tumor growth, sensitized cancer
cells to chemotherapy/irradiation-induced cell death. Finally, our data indicated that the peptide disrupting the
DNMT1/DMAP1 interaction increased the efficiency of temozolomide treatment.
Conclusion: Our data suggest that the DNMT1/DMAP1 interaction could be an effective anti-cancer target
and opens a new avenue for the development of new strategies to design DNMT inhibitors.
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Findings
Numerous reports have identified the occurrence of
global DNA hypomethylation as an oncogenic event in
human tumorigenesis. Indeed, DNMT1 silencing and
the disruption of the DNMT1/PCNA/UHRF1 complexes
were described as two events that promote the initia-
tion of tumorigenesis (malignant transformation from a
non-tumor cell to tumor cell) via the induction of global
DNA hypomethylation [1-4]. However, besides PCNA and
UHRF1 proteins, DNMT1 has multiple partners of inter-
action, the loss of which could potentially promote the
initiation of tumorigenesis or progression via the gener-
ation of the global DNA hypomethylation phenotype.
Disruption of certain DNMT1/protein-x interactions
Among the DNMT partners, we focused our analysis on
the impact of tumorigenesis on the disruption of the
DNMT1/PCNA, DNMT1/HDAC1, DNMT1/HP1β, DN
MT1/EZH2, DNMT1/Sp1, DNMT1/DMAP1 and DNM
T1/DNMT3b complexes (Figure 1A) [5-14].
To investigate the impact of the disruption of these
interactions on tumorigenesis, we transfected an astro-
cyte cell line (Astro#40) and a glioma cell line (U87)
with plasmid constructions encoding for peptides mim-
icking certain amino-acid regions implicated in the
interactions existing between DNMT1 and DMAP1,
DNMT3b, PCNA, EZH2, HDAC1, Sp1 and HP1β
(Figure 1A and Additional file 1: Figure S1).
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After 4 weeks of transfection/selection/amplification of
cells, proximity ligation in situ assays (P-LISA) revealed
that the 47–60, 197–212, 163–174, 430–444, 712–725,
791–802 and 885–900 peptides were specific to disrupting
the interactions between DNMT1 and DMAP1, DNMT3b,
PCNA, EZH2, HDAC1, Sp1 and HP1β, respectively. For
example, we observed in Astro#40 that the 197–212
peptide disrupted the DNMT1/DNMT3B interaction,
but not the DNMT1/HP1β, DNMT1/HDAC1, DNMT1/
Sp1, DNMT1/EZH2 and DNMT1/DMAP1 interactions
(Figure 1B). More generally, we noted that peptides
designed to specifically disrupt an interaction disrupted
only the targeted and expected interactions in Astro#40
and U87 cells (Additional file 2: Figure S2).
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Figure 1 Specific disruption of DNMT1/protein-x interactions. (A) Representation of DNMT1 with its functional domain (nuclear localization
signal: NLS, BAH1 and two domains, domain CXXC and its catalytic domain) and with amino acid domains of interaction with DMAP1, HDAC1,
Sp1, HP1β, EZH2, DNMT3b and PCNA according to the UniProt website and the literature. Amino acid sequences of peptides cloned in plasmid
and able to disrupt specific DNMT1/protein-x interactions are indicated in the “peptide” column; “untreated” indicates that cells were not treated
with a peptide encoding by a plasmid, i.e., that cells were only treated with a plasmid encoding for the NLS of interest. (B) Only the expression of
the 197–212 peptide promotes a significant decrease of the DNMT1/DNMT3b interaction in Astro#40 cells. Pictures (blue: DAPI staining; red:
DNMT1/DNMT3b interaction or close proximity) illustrate the specific disruption of the DNMT1/DNMT3b interaction or close proximity induced by
the expression of the 197–212 peptide, while the expression of the 47–60 peptide did not affect the DNMT1/DNMT3b interaction or close
proximity. Pictures are representatives of data obtained from 100 cells in three independent experiments. The graph illustrates the average ± SD
of these data. (C) Measure of the 5-methylcytosine (5 mC) level in cells (Astro#40 or U87) transfected by plasmid encoding for the indicated
peptides or pre-treated with procainamide (0.5 mmol/l each 5 days for 4 weeks) or 5aza-2deoxycytidine (1μM each 5 days for 4 weeks).
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Impact of the disruption of DNMT1/protein-x interactions
on the global DNA methylation level
We then investigated the impact of these disruptions on
the global level of DNA methylation, i.e., on the 5-me-
thylcytosine level. Two DNMT inhibitors (5aza-2deoxy-
cytidine and procainamide) were used as these drugs
induced global DNA hypomethylation (Figure 1C). In
agreement with our previous reports, the 163–174 plas-
mid was used as a peptide that induced global DNA
hypomethylation [3,4] (Figure 1C). Thus, we noted that
the disruption of DNMT1/HDAC1 and DNMT1/HP1β
interactions promoted a global decrease in the 5-me-
thylcytosine level in Astro#40 and U87 cells, while the
disruption of the DNMT1/EZH2, DNMT1/Sp1 and
DNMT1/DMAP1 interactions did not affect the 5-me-
thylcytosine level in these cells (Figure 1C).
Impact on tumorigenesis of the disruption of DNMT1/
protein-x interactions
Tumorigenic assays performed in Swiss nude mice re-
vealed that the subcutaneous injection of Astro#40 cells
treated 4 weeks with 5aza-2deoxycytidine and pro-
cainamide or transfected with plasmid encoding for the
163–174, 712–725 and 885–900 peptides generated tumor
formation in 3/5, 2/5, 5/5, 2/5 and 2/5 cases, respectively
(Figure 2A). Thus, we observed that gliomagenesis is in-
duced by the loss of DNMT1/PCNA, DNMT1/HDAC1
and DNMT1/HP1β interactions, i.e., under conditions that
also induced a decrease in the global DNA methylation
level. In parallel, we noted that the subcutaneous injec-
tions of U87 cells treated with 5aza-2deoxycytidine and
procainamide or transfected with plasmid encoding for
the 163–174, 712–725, 430–444, 885–900 and 197–212
peptides generated the formation of larger tumors as
compared to untreated U87 cells (Figure 2B). These data
suggest that the disruption of DNMT1/PCNA, DNMT1/
EZH2, DNMT1/DNMT3B, DNMT1/HDAC1 and DNM
T1/HP1β interactions acts such as an enhancer of tumori-
genesis. Thus, our work stratifies the specific disruption of
certain DNMT1/protein-x interactions into two categories
(Figure 2C). The first category includes the specific disrup-
tion of certain DNMT1/protein-x interactions acting as
inducers and/or enhancers of gliomagenesis (DNMT1/
PCNA, DNMT1/HDAC1 and DNMT1/HP1β, DNMT1/
EZH2, DNMT1/DNMT3b), i.e., acting as pro-tumori
genic-specific disruption of DNMT1/protein-x interac-
tions. The second category includes the specific disruption
of DNMT1/protein-x interactions devoid of any action on
gliomagenesis. This category is called neutral-tumori
genic-specific disruption of DNMT1/protein-x interac-
tions. Although absent in our data, we added a third
category called anti-tumorigenic-specific disruption of
DNMT1/protein-x interactions including the specific
disruption of DNMT1/protein-x interactions promot-
ing the decrease in tumorigenesis (Figure 2C).
Focus on two disruptions of DNMT1/protein-x
interactions devoid of action on gliomagenesis
In the absence of any observations of anti-tumorigenic-
specific disruptions of DNMT1/protein-x interactions, we
next analyzed whether the specific disruption of a DN
MT1/protein-x interaction devoid of action on glioma-
genesis could have an impact on the response to the stand-
ard GBM treatment combining temozolomide (TMZ) and
irradiation. For this, we measured the percentage of cell
death induced by a TMZ+ irradiation treatment of U87
cells transfected with the plasmids encoding for the
47–60 and 791–802 peptides (Additional file 3: Figure
S3). We noted that the 47–60 peptide, which induced
the disruption of the DNMT1/DMAP1 interaction, in-
creased the percentage of TMZ + irradiation-induced
cell death, while the 791–802 peptide, which induced
the disruption of the DNMT1/Sp1 interaction, had no
effect on the percentage of TMZ + irradiation-induced
cell death (Figure 2D). In addition, our data also indi-
cated that the 5aza-2deoxycytidine and procainamide
treatments and the 163–174 peptide induced a pheno-
type resistant to TMZ + irradiation cell death since the
percentage of TMZ-irradiation-induced cell death sig-
nificantly decreased under these conditions (Figure 2D).
Taken together, these data indicate that, among the con-
sidered peptides and DNMT1 inhibitors, only the spe-
cific 47-60-induced disruption of the DNMT1/DMAP1
interaction increased the percentage of TMZ + irradi-
ation-induced cell death without promoting or increas-
ing the tumorigenesis. Thus, we conclude that the
specific inhibition of the DNMT1/DMAP1 interaction
is a neutral-tumorigenic-specific inhibition of DNMT1/
protein-x interaction harboring the capacity to sensitize
cells to TMZ + irradiation-induced cell death.
Disruption of DNMT1/DMAP1 interactions enhances the
anti-tumor effect of TMZ treatment in mice
To investigate this point, established tumors were treated
with TMZ, TMZ + 47-60DNMT1 and mutated 47-60DNMT1
(m47-60DNMT1) (Additional file 4: Figure S4). Mice re-
ceived 6 weeks of treatment as in treatment of human
GBM, and tumor weight was analyzed 2 weeks after the
end of the treatment. As illustrated in Figure 2E, we first
noted that TMZ treatment reduced the tumor weigh of
U87-induced glioma. Second, we observed that the
addition of 47-60DNMT1 increased the efficiency of TMZ
treatment and decreased tumor growth, while m47-
60 DNMT1 had no effect on the efficiency of TMZ treat-
ment (since this peptide does not disrupt the DNMT1/
DNMAP1 interaction; Additional file 5: Figure S5). Thus,
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Figure 2 Impact of specific inhibition of DNMT1/protein-x interaction. (A) Tumorigenicity test of Astro#40 cells transfected with plasmids
encoding for indicated peptides or pre-treated with procainamide. For each condition, five subcutaneous injections of 106 cells were performed
in Swiss nude nice. Picture illustrates the tumor obtained (or not) 5 weeks after injections. (B) Tumorigenicity test of U87 cells transfected with
plasmids encoding for indicated peptides or pre-treated with epigenetic drugs. For each condition, three subcutaneous injections of 106 cells
were performed in Swiss nude mice. Graph illustrates the average ± SD of these data. Picture illustrates representative tumors obtained 4 weeks
after injections. (C) Effect of different DNMT inhibitor strategies. DNA methylation governs the expression of tumor suppressor genes (TSG) but
also of oncogenes and DNA repeat element and retrotransposons (whose demethylation and/or expression promotes the tumorigenesis). By
using an unspecific DNMT inhibitors (5aza-2deoxycytidine) or a specific DNMT1 inhibitor (procainamide), we postulate that we induced the
hypomethylation not only of TSG but also of the oncogenes and retrotransposons. By reducing the effect of DNMT1 inhibition to certain specific
DNMT/protein-x interactions, we still keep the opportunity to promote the expression of the TSG without promoting the hypomethylation-
induced activation of retrotransposons and oncogenes. (D) Analysis of TMZ + irradiation-induced cell death in U87 cells. Percentages of cell death
were evaluated by using a trypan blue stain 0.4%, and the Countess® Automated Cell Counter (Life Technology, France). Graph illustrates the
average ± SD of three independent experiments. (E) Impact of the addition of 47-60DNMT1 on TMZ treatment in an in vivo model of glioma. After
the tumor establishment, mice were treated with TMZ and TMZ + 47-60DNMT1 (Additional file 4: Figure S4). Two negative controls were used:
“untreated” represents a treatment with DMSO “m47-60DNMT1” symbolized a co-treatment using TMZ and mutated 47-60DNMT1. Graph illustrates
the average ± SD of five independent experiments.
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our data identify 47-60DNMT1 as an enhancer of TMZ
treatment.
Discussion
To summarize, our data indicate that the specific inhib-
ition of certain DNMT1/protein-x interactions (DNM
T1/PCNA interaction, for example) and the use of a spe-
cific DNMT1 inhibitor (procainamide) or unspecific DN
MT1 inhibitor (5-aza-2deoxycytidine) could be used as a
treatment, acting as inducers and/or enhancers of tumori-
genesis. Our data indicate that the specific inhibition of the
DNMT1/DMAP1 interaction acts as a tumor suppressor-
like event since the disruption of the DNMT1/DMAP1
interaction increased TMZ+ irradiation-induced cell death
without promoting the initiation and progression of tu-
morigenesis. Consequently, we distinguish between among
the neutral-tumorigenic-specific inhibition of DNMT1/
protein-x interaction and the tumor suppressor-like
neutral-tumorigenic-specific inhibition of DNMT1/
protein-x interaction (Figure 2C).
Using this example, our data underline the necessity to
consider the interaction partners of DNMT1 and not
only the DNMT1 structure or activity to develop a
DNMT1 inhibitor. In other terms, our data introduce,
for the first time, the notion of protein/protein inhib-
ition into the development of DNMT inhibitors. Indeed,
without being innovative in the development of drugs or
small molecules for a therapeutic application, this strat-
egy is novel in the conception/research of DNMT inhibi-
tors since the identification of DNMT inhibitors is, to
date, based on docking-based virtual screening methods,
the screening of natural products, the design and gener-
ation of derivatives of DNMT inhibitors already known,
or molecular modeling of DNMT inhibitors by using
crystal structure studies of DNMTs [15-19]. Thus, like
ABT-737 and MI-129, two compounds targeting specific
protein-protein interactions (pro-apoptotic/anti-apopto-
tic and p53/MDM2 interactions, respectively) have
opened a new area in targeted therapy; our data argue
that the targeting of certain DNMT1/protein-x interac-
tions opens a new area in the development of targeted
epigenetic therapy.
However, despite its promising character, the develop-
ment of specific inhibitors of DNMT1/protein-x interac-
tions requires the identification of tumor suppressor-like
neutral-tumorigenic-specific inhibition of DNMT1/pro-
tein-x interaction or anti-tumorigenic-specific disruption
of certain DNMT1/protein-x interactions. Thus, studies
are ongoing in our laboratory to identify a DNMT1/pro-
tein-x-including complex promoting the methylation-
induced silencing of the tumor suppressor gene without
being implicated in the methylation-induced silencing of
oncogenes.
Concerning the use of 5aza-2deoxycytidine and pro-
cainamide, we are aware that the tumorigenesis processes
associated with the use of these drugs are obtained after a
long exposure. However, 4 weeks is not a long period
on the scale of the majority of the chemotherapeutic
treatments that last several months. Regardless, our
data provide “a warning” concerning the use of DNA
demethylating agents as an anti-cancer therapy and
provide proof reinforcing the necessity of using specific
DNMT inhibitors or unspecific DNMT1 inhibitors with
an adequate and optimized dose schedule, as already
described by several publications [20,21]. Besides, sev-
eral publications also argue that the use of DNMT in-
hibitors could promote oncogene activation [22,23].
Thus, Chik and Szyf [22] report that 5aza-2deoxycyti-
dine activated both silenced tumor suppressor genes
and pro-metastatic genes by demethylation, raising the
concern that it could promote metastasis [22]. Associ-
ated with our results, these data support the idea of de-
veloping specific DNMT1, particularly developing a
specific inhibitor of DNMT1/protein-x interaction.
Methods
Proximity ligation in situ assay (P-LISA)
P-LISA is a technology permitting the visualization of
stable and transient interactions at endogenous protein
levels directly in situ [20]. Briefly, two primary antibodies
raised in different species recognize the target antigen or
antigens of interest. Species-specific secondary antibodies,
called PLA probes, each with a unique short DNA strand
attached to it, bind to the primary antibodies. When the
PLA probes are in close proximity (< 40 nm), the DNA
strands can interact through a subsequent addition of two
other circle-forming DNA oligonucleotides. After ligating
the two added oligonucleotides, creating a circle DNA
molecule, they are amplified via rolling circle amplifica-
tion. After amplification, several-hundredfold replication
of the DNA circle has occurred, and labeled complemen-
tary oligonucleotide probes highlight the product. The
resulting high concentration of fluorescence in each
single-molecule amplification product is easily visible as
a distinct bright dot when viewed with a fluorescence
microscope.
Cells were cultured for 24 h on cover slips. Cells were
then fixed with 4% paraformaldehyde in PBS, pH 7.4, for
15 min at room temperature. Permeabilization was per-
formed with PBS containing 0.5% Triton X-100 for 20 min
at room temperature. Blocking, staining, hybridization,
ligation, amplification and detection steps were realized
according to the manufacturer’s instructions (Olink
Bioscience). All incubations were performed in a humi-
dity chamber. Amplification and detection steps were
performed in a dark room. Fluorescence was visualized
by using the Axiovert 200M microscopy system (Zeiss,
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Le Pecq, France) with the ApoTome module (X63 and
numerical aperture 1.4). Preparations were mounted
using ProLong® Gold antifade reagent with DAPI
(InVitrogen, France). Picture acquisition was realized in
structured illumination microscopy [24]. Finally, the im-
ages were analyzed using the freeware “BlobFinder” avail-
able for download from www.cb.uu.se/~amin/BlobFinder.
Thus, we obtained the number of signals per nuclei since
nuclei can be automatically identified.
Plasmid construction and transfection
To express peptides in cells, we subcloned in pcDNA3.3
(Life Technology, France) the sequences encoding for
the indicated peptides. In addition, the NLS sequence
(PKKKRKV) was added to the sequences encoding for
the indicated peptides in order to address the peptides
in the nucleus. Tranfections were next realized by using
2.105 cells, 5 μg of plasmid and Lipofectamine™ 2000 re-
agents (Life Technology, France). Selection was realized
by adding 500 μg/ml of Geneticin selective antibiotic in
complete medium of cell culture for 3 weeks. Next, 1
week was used to amplify the cells. Veracity of transfec-
tion was determined by PCR analyses using primers di-
rected against pcDNA3.3 (ACGTTGTCACTGAAGCGG
and CCTGATGCTCTTCGTCCA) and by the fact that
each plasmid affects the DNMT1/protein-x interaction
of interest.
Measure of the 5-methylcytosine level
DNA was extracted using the QiaAmp DNA mini Kit
(Qiagen, France). The quantification of 5-methylcytosine
is performed by using the Methylamp Global DNA
methylation Quantification kit (Euromedex-Epigenetiek,
France).
Tumorigenicity assay
Cultured cells were harvested by trypsinization, washed
and resuspended in saline buffer. Cell suspensions were
injected s.c. as 106 cells in 0.2 ml volume in the flank of
7-/8-week-old nude NMRI-nu female mice (Janvier,
France).
Additional files
Additional file 1: Figure S1. Representation of the pcDNA3.3 plasmid
used to express the indicated peptides in cells. For each peptide, the
amino acid position, sequences and corresponding cDNA sequences are
indicated in the table.
Additional file 2: Figure S2. Graphs illustrate the impact of the
expression of the considered peptide on the indicated DNMT1/protein-x
interaction of close proximity. Graph illustrates the average ± SD obtained
from 100 cells in three independent experiments. *Only the
corresponding interaction was significantly decreased (p < 0.05, t-test) by
the considered peptides in comparison with the data obtained from
untreated cells. “Untreated” indicates that cells are not transfected by a
plasmid encoding for a peptide or are not treated with a DNMT inhibitor.
Thus, this condition is used as a control. For each peptide, the specificity
of inhibition of disruption of one considered peptide is reinforced by the
use of six other peptides.
Additional file 3: Figure S3. Schematic representation of the
TMZ + irradiation treatment administered to the cells.
Additional file 4: Figure S4. Schematic representation of the
treatments administered to mice.
Additional file 5: Figure S5. Effect of 47-60DNMT1 and m47-60DNMT1
on the DNMT1/DMAP1 interaction. Graphs illustrate the impact of the
considered peptide on the indicated DNMT1/protein-x interaction of
close proximity. Graph illustrates the average ± SD obtained from 100
cells in three independent experiments. *Only the corresponding
interaction was significantly decreased (p < 0.05, t-test) by the considered
peptides in comparison with the data obtained from untreated cells.
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